BRIM Biotechnology's Total Assets for the quarter that ended in Dec. 2025 was NT$1,827.74 Mil.
During the past 12 months, BRIM Biotechnology's average Total Assets Growth Rate was 19.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 87.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 47.10% per year.
During the past 7 years, BRIM Biotechnology's highest 3-Year average Total Assets Growth Rate was 101.60%. The lowest was -17.50%. And the median was 92.85%.
Note:
The Net Income data used here is four times the quarterly (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
BRIM Biotechnology's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
BRIM Biotechnology Total Assets Related Terms
BRIM Biotechnology Total Assets Historical Data
* Premium members only.
The historical data trend for BRIM Biotechnology's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
BRIM Biotechnology's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BRIM Biotechnology (TPE:6885) has a Total Assets of NT$1,827.74 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on BRIM Biotechnology and its competitors.
Is BRIM Biotechnology's Total Assets too high?
BRIM Biotechnology's current Total Assets is NT$1,827.74 Mil. Overall, BRIM Biotechnology has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BRIM Biotechnology's Total Assets compare to VRTX and REGN?
BRIM Biotechnology's Total Assets of NT$1,827.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on BRIM Biotechnology and its competitors. BRIM Biotechnology's current Total Assets is NT$1,827.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BRIM Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, BRIM Biotechnology (TPE:6885) is currently considered Possible Value Trap. The stock's GF Value™ is NT$486.91, compared to a current price of NT$21.75 — trading 95.5% below its estimated fair value. The current Total Assets is NT$1,827.74 Mil. BRIM Biotechnology's overall GF Score™ is 40/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For BRIM Biotechnology (TPE:6885), the current Total Assets is NT$1,827.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BRIM Biotechnology (TPE:6885) Overvalued in 2026?
Based on GuruFocus' analysis, BRIM Biotechnology stock appears to be undervalued.
The current stock price of NT$21.75 is trading 95.5% below its estimated GF Value™ of NT$486.91.
GuruFocus considers BRIM Biotechnology to be Possible Value Trap.
Key valuation signals for TPE:6885:
Total Assets: NT$1,827.74 Mil
GF Value™: NT$486.91 vs. price of NT$21.75 (95.5% below fair value)
No single metric tells the full story. See the TPE:6885 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BRIM Biotechnology Inc is engaged in the research and development of new drug translation, genetic testing services, research and development services in natural and engineering sciences, and medical laboratory services. The Group has two reportable operating segments: BRIM's main business is new drug translational development services, and Compass's main business is gene sequencing and testing technology services. It generates the majority of its revenue from the BRIM segment. Geographically, it operates in Taiwan, Japan, and the USA. It generates the majority of its revenue from Taiwan.
40GF Score
Get the complete analysis for TPE:6885
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6885 has been successfully added to your 
